Literature DB >> 1137357

Clinical pharmacology of sisomicin.

V Rodriguez, G P Bodey, M Valdivieso, R Feld.   

Abstract

Studies were conducted in 30 patients with neoplastic diseases. Twelve patients received sisomicin intramuscularly at doses of 20 mg/m(2) and 40 mg/m(2). The mean peak serum concentration occurred at 1 h and was 2.5 mug/ml and 4.0 mug/ml, respectively. Ten patients received intravenous sisomicin at doses of 30 mg/m(2) during 30-min infusion. Mean peak serum level determined at 30 min was 5.1 mug/ml. The levels gradually decreased and at 6 h was 0.6 mug/ml. The serum half-life was 160 min. Serum levels determined in eight patients who received sisomicin by continuous infusion at doses of 30 mg/m(2) every 6 h were greater than 1.4 mug/ml during the 6-h period. The urinary excretion of sisomicin during the 6-h period after intramuscular administration of 20 mg/m(2) and 40 mg/m(2) was 49 and 61%, respectively. The pharmacology of sisomicin is similar to gentamicin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1137357      PMCID: PMC429068          DOI: 10.1128/AAC.7.1.38

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  LABORATORY AND CLINICAL STUDIES OF GENTAMICIN, A NEW BROAD-SPECTRUM ANTIBIOTIC.

Authors:  R J BULGER; S SIDELL; W M KIRBY
Journal:  Ann Intern Med       Date:  1963-11       Impact factor: 25.391

2.  Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic.

Authors:  M J Weinstein; J A Marquez; R T Testa; G H Wagman; E M Oden; J A Waitz
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

3.  Antibiotic 6640. 3. Biological studies with antibiotic 6640, a new broad-spectrum aminoglycoside antibiotic.

Authors:  J A Waitz; E L Moss; E M Oden; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1970-11       Impact factor: 2.649

  3 in total
  11 in total

1.  Radioimmunoassay of sisomicin.

Authors:  A Broughton; J E Strong; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion.

Authors:  G P Bodey; H Y Chang; V Rodriguez; D Stewart
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

4.  Comparison of the antibacterial activities of sisomicin and gentamicin against gram-negative bacteria.

Authors:  B R Meyers; B Leng; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

5.  Inhibition of L5178Y cells in culture by methotrexate and antibiotics.

Authors:  P L Chello; H W Bruckner
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

6.  Pharmacokinetic study of sisomicin in humans.

Authors:  M Chung; J J Schrogie; S Symchowicz
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

7.  Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.

Authors:  J C Pechère; M M Pechère; R Dugal
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

8.  Comparison of activity of sisomicin and gentamicin in mouse protection tests with gram-negative bacilli.

Authors:  B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

9.  Pharmacokinetic parameters of sisomicin.

Authors:  B R Meyers; S Z Hirschman; S Yancovitz; B Ribner
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

10.  Clinico-pharmacological studies of sisomicin in ill children.

Authors:  M I Marks; A Vose; S Hammerberg; R Dugal
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.